Employees: 2,718
Size Jinhe Biotechnology (002688.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $550M, the 3461st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.78 on 18 Nov 2026.
Performance Over six months the shares fell 18.7%, against -18.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue grew 7.0% over the last twelve months (peer median +0.7%); the operating margin is 5.1% (peer median 6.8%).
Valuation It trades at 8.9× forward earnings against a peer median of 11.3× (cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.94B | CN¥2.87B | CN¥2.37B | CN¥2.16B | CN¥2.11B |
| Revenue growth | — | +21% | +10% | +3% | — |
| Gross profit | CN¥1.16B | CN¥869M | CN¥709M | CN¥565M | CN¥539M |
| EBITDA | n/a | CN¥542M | CN¥384M | CN¥331M | CN¥288M |
| Net income | CN¥21.6M | CN¥27.6M | CN¥100M | CN¥86.5M | CN¥75.6M |
| Free cash flow | CN¥141M | CN¥147M | CN¥135M | -CN¥256M | -CN¥280M |
| Capital expenditure | CN¥372M | CN¥320M | CN¥362M | CN¥457M | CN¥402M |
| Total debt | CN¥2.30B | CN¥2.45B | CN¥2.52B | CN¥2.37B | CN¥1.61B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002688.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | -11.4% | 4th highest of 20 |
| 6-month return | -18.7% | -18.3% | 10th highest of 19 |
| Distance from 52-week high | -31.7% | -42.8% | 5th highest of 20 |
| Revenue growth (TTM) | +7.0% | +0.7% | 9th highest of 20 |
| Operating margin | 5.1% | 6.8% | 8th lowest of 19 |
| Forward P/E | 8.9× | 11.3× | cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 1.0% | -3.1% | 5th most demanding of 10 |
| Growth delivered (Del g) | +9.7% | +11.1% | 5th lowest of 10 |
| Hurdle (Req g minus delivered) | -8.7 pp | -9.9 pp | 5th most demanding of 10 |
| ROIC minus cost of capital | +0.7 pp | -3.5 pp | 4th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 8.9× | 1.0% | +9.7% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 32.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | n/a | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 36.2× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | n/a | 49.3% | -1.5% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 10.2× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |